This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Alkermes Focuses on Pipeline, Depends on Partners for Funds
by Zacks Equity Research
Alkermes (ALKS) has an impressive pipeline and is focused on the development of its candidates.
PDL BioPharma (PDLI) Q4 Earnings Top Mark, Revenues Fall Y/Y
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings exceed estimates in Q4. Lower royalties as well as weak product sales induce a downfall in year-over-year revenues.
The Zacks Analyst Blog Highlights: Visa, Honeywell, Biogen, Humana and EOG Resources
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Visa, Honeywell, Biogen, Humana and EOG Resources
Celgene (CELG) Submits Application for MS Drug in Europe
by Zacks Equity Research
Celgene (CELG) submits application for MS drug, ozanimod to the European Medicines Agency.
Top Stock Reports for Visa, Honeywell & Biogen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Visa (V), Honeywell (HON) and Biogen (BIIB).
Biotech Stock Roundup: BIIB to Acquire Nightstar, Other Pipeline News & More
by Zacks Equity Research
Key highlights of the past week are merger agreements plus regulatory and pipeline developments.
Biogen to Acquire Gene-Therapy Company Nightstar for $800M
by Zacks Equity Research
Biogen (BIIB) to acquire gene-therapy company, Nightstar Therapeutics to accelerate entry into ophthalmology space.
Company News For Mar 5, 2019
by Zacks Equity Research
Companies in the news are; PLCE, BIIB, NITE, ASND and TAK
AbbVie Gets CHMP Nod for Psoriasis Candidate Risankizumab
by Zacks Equity Research
AbbVie (ABBV) gets positive opinion of the CHMP recommending marketing approval for risankizumab for the treatment of moderate-to-severe plaque psoriasis.
Alkermes' (ALKS) and Biogen's NDA for BIIB098 Accepted by FDA
by Zacks Equity Research
The FDA accepts Alkermes (ALKS) and partner Biogen's NDA for diroximel fumarate and sets an action date in the fourth quarter of 2019.
Novartis In-Licenses Rights to Heart Candidate From Ionis
by Zacks Equity Research
Novartis (NVS) in-licenses rights to develop and commercialize TQJ230 from Ionis Pharmaceuticals for treating targeted cardiovascular diseases.
AbbVie's RA Candidate Upadacitinib Gets FDA Priority Review
by Zacks Equity Research
AbbVie's (ABBV) new drug application for its late-stage candidate, upadacitinib, gets a priority review status from the FDA for treating rheumatoid arthritis in adult patients.
Alkermes (ALKS) Q4 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Alkermes' (ALKS) earnings and sales exceed estimates in the fourth quarter of 2018.
Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings
by Sanghamitra Saha
Biotech stocks came up with mixed earnings and weighed on the related ETFs in the key reporting season.
The Zacks Analyst Blog Highlights: Visa, Charter, Biogen, BP and BB&T
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Visa, Charter, Biogen, BP and BB&T
Top Research Reports for Visa, Charter Communications & Biogen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Visa (V), Charter Communications (CHTR) and Biogen (BIIB).
Alkermes Sinks as FDA Refuses to Approve Depression Drug
by Zacks Equity Research
Alkermes (ALKS) falls almost 5% on a Complete Response Letter from the FDA for its pipeline candidate, ALKS 5461for major depressive disorder (MDD).
Biogen (BIIB) Q4 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Biogen (BIIB) beats estimates for both earnings and sales in the fourth quarter of 2018, driven by higher sales of Spinraza.
Biogen (BIIB) Beats Revenues and Earnings Estimates in Q4
by Zacks Equity Research
Biogen (BIIB) beat estimates both for earnings and sales in Q4. Its newest drug Spinraza performed well in the quarter.
Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FLQL
Drug/Biotech Stock Earnings on Jan 29: PFE, AMGN, BIIB & AGN
by Zacks Equity Research
Four drug/biotech stocks are scheduled to release their fourth-quarter results on Jan 29. Let's take a look at how these companies are poised ahead of their earnings release.
What's Behind the Biotech ETF Rally to Start 2019?
by Sanghamitra Saha
Biotech ETFs have been riding on the wave of mergers and acquisitions as well as drug approvals.
The Zacks Analyst Blog Highlights: Pfizer, Biogen, Schwab, Sysco and Philips
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Biogen, Schwab, Sysco and Philips
Biogen (BIIB) Q4 Earnings Coming Up: What's in the Cards?
by Zacks Equity Research
While sales of Biogen's (BIIB) MS franchise are expected to be stable in the fourth quarter that of Spinraza are likely to increase.
Top Stock Reports for Pfizer, Biogen & Schwab
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), Biogen (BIIB) and Schwab (SCHW).